SC Pharmaceuticals(SZ:002693) Sou Hu Cai Jing·2025-07-09 12:57Core Viewpoint - *ST Shuangcheng has no current plans to acquire a semiconductor company and is actively taking measures to mitigate the risk of delisting by enhancing its marketing strategies and international sales efforts [1] Group 1: Marketing and Sales Strategies - The company is adapting to new national medical insurance and procurement policies to increase sales volume of existing products [1] - Efforts are being made to enhance international sales, particularly following the approval of its injectable paclitaxel (albumin-bound) for legal sale in the U.S., which boosts market competitiveness [1] Group 2: Export and Production - The company aims to maintain existing customer orders in its peptide business while expanding its customer base and utilizing the increased purification capacity of its expanded peptide workshop [1] - Active promotion of pending product approvals and ANDA submissions in the U.S., Canada, and other countries is underway, alongside efforts to secure more CDMO projects and technical collaborations [1] Group 3: CMO Cooperation and Cost Control - The company is leveraging its GMP capabilities in sterile products to pursue external CMO collaborations, particularly with major clients [1] - Continuous cost control measures are being implemented, focusing on optimizing personnel configuration, enhancing efficiency, ensuring reasonable procurement, and monitoring expense rationality [1]